Bank of Montreal Can grew its stake in Retrophin Inc (NASDAQ:RTRX) by 51.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 181,416 shares of the biopharmaceutical company’s stock after buying an additional 61,634 shares during the quarter. Bank of Montreal Can owned 0.46% of Retrophin worth $3,823,000 as of its most recent filing with the SEC.
Other hedge funds have also bought and sold shares of the company. Legal & General Group Plc increased its holdings in shares of Retrophin by 4.3% in the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 355 shares during the period. Trexquant Investment LP acquired a new position in Retrophin during the third quarter worth $203,000. Dynamic Technology Lab Private Ltd purchased a new stake in Retrophin during the third quarter worth $212,000. Campbell & CO Investment Adviser LLC purchased a new stake in Retrophin during the third quarter worth $249,000. Finally, GSA Capital Partners LLP purchased a new stake in Retrophin during the second quarter worth $279,000.
Shares of Retrophin Inc (NASDAQ:RTRX) traded up $0.79 on Wednesday, reaching $21.74. The company had a trading volume of 277,500 shares, compared to its average volume of 260,019. Retrophin Inc has a 1 year low of $15.55 and a 1 year high of $26.44. The company has a quick ratio of 3.83, a current ratio of 3.88 and a debt-to-equity ratio of 0.15.
RTRX has been the topic of several recent research reports. Zacks Investment Research upgraded Retrophin from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 4th. BidaskClub lowered Retrophin from a “buy” rating to a “hold” rating in a research note on Saturday, December 30th. Finally, ValuEngine lowered Retrophin from a “hold” rating to a “sell” rating in a research note on Monday, November 20th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Retrophin currently has a consensus rating of “Hold” and an average target price of $44.00.
TRADEMARK VIOLATION WARNING: “Bank of Montreal Can Has $3.82 Million Position in Retrophin Inc (RTRX)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/bank-of-montreal-can-purchases-61634-shares-of-retrophin-inc-rtrx.html.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.